The development of organ-chip technology represents an amazing breakthrough in the modern biomedical research, which enables scientists to direct their research at real human organs and tissues. The incredible market dynamics of the organ-on-a-chip reveal the increasing demand of the precise and fast alternatives to the conventional methods of in vitro and in vivo experiments. Among the factors contributing to this market is the growing demand for valuable models that can recreate the multifaceted happenings as well as the physiologic situations that are common in human body organs. To ensure the safety and effectiveness of drugs as well as the novel drug candidates, the organ-on-a-chip technology will come in handy as it provides a testing platform in a physiologically-relevant microenvironment, hence, lowering the risk of failure at the later stages of medical product development.
The market for organ-on-a-chip technology is also in a situation where there is a great growth due to the increased level of awareness of the barriers that animal testing is associated with. The ethical problem in conjunction with the inability of a laboratory animal to recreate the exact human reactions in a human experiment lead scientists to find other methods for scientific research. Organ / vessel on a chip technologies that contain human organs and their function responses have a vast potential to replace by the humane and more precise pre-clinical testing. The alteration of paradigmatic thinking clearly plays a significant role in the growing uptake of organ-on-a-chip technology in the pharmaceutical industry, academia, as well as throughout research organizations.
Interactions and connections among the major stakeholders involved in organ-on-a-chip market are posing its increase greatly. While the technology is still in its infancy, industrial sectors are joining hands to use the knowledge and resources they best possess and develop fully functional and commercially viable organ-on-a-chip systems. Such partnerships significantly shorten the time of prototype realization but also offer a broader approach through standardization and validation of the technology and overcome regulatory worries and hence have a high acceptance level.
Coming to the second point, the market dynamics are modified with the more research and development capital being poured. Governments, investors in private firms, and funders are more confident with this unique technology in the hopes that it will efficiently move the drug discovery industry to a higher stride and personalized drugs closer to becoming reality. From this, the financial backup is growing the technology of the new on the chip model, which is sophisticated and specific for various uses cases. The flow of funds on a regular basis that are responsible for resolving technical obstacles and ensuring mass production and replicability of Organ-on-a-chips are the essential components.
Report Attribute/Metric | Details |
---|---|
Segment Outlook | Organ Type, Application and End-User Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW) Key Vendors CN Bio Innovations Limited (UK), Emulate, Inc. (US), TissUse GmbH (Germany), MIMETAS BV (Netherlands), Hµrel Corporation, Nortis, Inc. (US), InSphero (Switzerland), TARA Biosystems, Inc. (US), Axosim (US), Organovo Holdings Inc. (US), BioIVT (US), HemoShear Therapeutics, LLC (US) Key Market Opportunities Ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities Key Market Drivers· Increasing investment by major companies in organ-on-a-chip research & development· The growing demand for drug screening with organs-on-a-chips |
The Organ-on-a-chip Market size is expected to reach USD 0.23 Billion by 2032 at 11.7% CAGR during the forecast period 2023-2032.
Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers, which contain multiple live human cells in a 3D culture that simulate vital physiological functions of body organs. These cells are placed in an environment that artificially replicates aspects of the human body, such as morphology, movement, flow, electrical stimuli, and liquid gradients.
There has been an increase in the number of collaborative sales agreements between pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to increase the growth rate of this Organ-On-a-Chip market in the future further.
The small size of the market is mainly because OOCs have not yet been fully commercialized. They are still in the research and development phase and are being used by a limited number of end-users.
There has been a notable rise in the prevalence of joint sales agreements between pharmaceutical corporations and university spin-offs, accompanied by the introduction of novel advanced models of organ-on-a-chip (OOC) systems onto the market. The future growth rate of the Organ-On-a-Chip market is likely to be further increased by the forthcoming development of enhanced organ-specific models and human-on-chip models.
Furthermore, the market growth is expected to be driven by enhanced drug screening procedures, which have led to increased research and development activities by key industry players. Additionally, strategic efforts and developments in technology are also projected to contribute to the growth of the market in the forecast future.
The market growth is primarily influenced by two key factors: the significant cost reduction in drug development achieved via the use of organ-on-a-chip (OOC) models, and the availability of funds from both government and non-government groups. The projected growth at a high compound annual growth rate (CAGR) may be attributed to the growing number of collaborative sales agreements between pharmaceutical firms and university spin-offs, as well as the introduction of new sophisticated models of organ-on-a-chip (OOC) technology in the market.
The future growth rate of the Organ On a Chip market is likely to be further enhanced by the forthcoming introduction of sophisticated organ-specific models and human-on-chip models.
In June 2024: Emulate, Inc. launched a new version of their organ-on-a-chip platform designed to better simulate human liver function. This upgrade is expected to improve the accuracy of drug metabolism studies.
In April 2024, CN Bio secured $21 million in the first close of their Series B investment round, with Bayland Capital and CN Innovations Holdings Ltd contributing significantly.
The ability of OOC models to reduce drug development costs drastically and grants by government and non-government entities are the major factors influencing the market growth. It is expected to rise at this high CAGR due to an increase in the number of collaborative sales agreements between the pharmaceutical companies and university spin-offs and the entry of new advanced models of OOCs into the market. The anticipated launch of advanced organ-specific models and human-on-chip models is expected to further increase the growth rate of this Organ On a Chip market in the future. Grants by government and non-government entities have been the key drivers for the global OOC industry to date. The ability of OOC models to cut drug development costs drastically will be a key market driver in the future.
Moreover, improved drug screening methodologies increased R&D by major players, strategic initiatives and increasing technological advancements are also anticipated to fuel the market growth during the forecast period.
Drivers
Restraints
Americas: The largest regional Organ on a Chip market. Owing to the availability of a wide range of products and services offered by major players, including customized designing of new chips with specific organ arrangement and increase in toxicological testing of chemicals on the different types of organ cells.
Europe: It is the second-largest market and expected to grow at a steady rate during the forecast period. Establishment of major OOC providers in five countries of the European Union (EU), namely the UK, Germany, France, Italy, and Spain; government initiatives and government funding to research institutes; collaborations among companies and universities to develop innovative OOCs, and a well-developed healthcare infrastructure expected to drive the market growth.
Asia-Pacific: The fastest-growing regional Organ on a Chip market. Furthermore, the region has a supportive regulatory framework for the approval of OOCs in South Korea, Australia, Japan, and China. This factor, along with a high prevalence of chronic diseases, will drive the market during the forecast period.
Middle East & Africa: The Middle Eastern Organ on a Chip market is expected to show more growth as compared to the African market, owing to the presence of developed countries such as Saudi Arabia and Oman in the region.
The agreement entails the inclusion of LifeNet Health's hepatic cells, which have been validated for high quality and MPS, in CN Bio's Non-Alcoholic Steatohepatitis (NASH) 'in-a-box' kit. Alternatively, customers can directly obtain these cells from LifeNet Health. This collaboration offers customers a simplified solution to replicate the advanced in vitro liver models developed by the Company and enhance the success of their assays.
In November 2023,Emulate Inc. announces the launch of its new Liver-on-a-Chip platform, a microfluidic device that can be used to model liver function in vitro. The Liver-on-a-Chip platform is designed to provide researchers with a more accurate and reliable way to study liver diseases and develop new treatments.
InSphero AG announces the launch of its new Skin-on-a-Chip platform, a microfluidic device that can be used to model skin function in vitro. The Skin-on-a-Chip platform is designed to provide researchers with a more accurate and reliable way to study skin diseases and develop new treatments.
In November 2023,Organovo Inc. announces the launch of its new Ex Vivo Kidney platform, a bioengineered kidney that can be used to model kidney function in vivo. The Ex Vivo Kidney platform is designed to provide researchers with a more accurate and reliable way to study kidney diseases and develop new treatments.
In April 2023,The development of a multi-organ chip on-a-chip, utilizing 3D cell printing technology, has been successfully accomplished by a team of researchers from Pohang University of Science and Technology (POSTECH) in South Korea and Eunpyeong St. Mary's Hospital of the Catholic University of Korea. This innovative chip aims to closely mimic the pathological conditions associated with type 2 diabetes (T2D). In order to simulate the pathogenic characteristics of diabetes and its consequences, the study team produced bioinks sourced from the pancreas, adipose tissue, and liver, which exhibit significant associations with Type 2 Diabetes (T2D).
Subsequently, the researchers utilized 3D cell printing techniques to fabricate a multi-organ chip on-a-chip platform, strategically designed to accurately replicate the pathological features associated with Type 2 Diabetes (T2D).
Organ-On-a-Chip Market Key Players
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)